Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Total net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments$32.6 million cash balance at September 30, 2025Company remains on track to …
Jetzt den vollständigen Artikel lesen